Teng Zhang | Gynecologic Oncology | Young Scientist Award

Posted on by ScienceFather

Ms. ā€ŒTeng Zhang |Gynecologic Oncology |Young Scientist AwardĀ 

Ms at Qilu Hospital of Shandong University, China

Ms. Teng Zhang is an accomplished Attending Doctor in the Department of Obstetrics and Gynecology at Qilu Hospital of Shandong University. With a Ph.D. and Master’s degree from Cheeloo College of Medicine, Shandong University, and a Bachelor’s degree from Jining Medical College, Ms. Zhang has extensive experience in clinical practice and research. Notable achievements include publications on cervical cancer in high-impact journals and awards in English teaching competitions. Dr. Zhang’s research focuses on fertility-sparing treatments, m6A methylation, and immune cell variations in cervical cancer, underscoring a strong commitment to advancing women’s health.

Profile

 

šŸŽ“ Education Background

Sept. 2015 – Sep. 2018: Ph.D., Cheeloo College of Medicine, Shandong University. Sept. 2013 – Sep. 2015: Master, Cheeloo College of Medicine, Shandong University. Sept. 2008 – Jun. 2013: Bachelor of Medicine, Jining Medical College. Sept. 2005 – Jun. 2008: Qingdao No.2 Middle School

šŸ’¼ Research/Work Experience

July 2022 – Present: Attending Doctor, Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University. Nov. 2018 – June 2021: Resident, Department of Gynecology and Obstetrics, Qilu Hospital of Shandong University. June 2016 – June 2017: Visiting Scholar, Griffith University, Australia

šŸ† Scholarships and Awards

2023: Young Teachers English Teaching Competition, Second Prize, Cheeloo College of Medicine, Shandong University, 2021: The First “Guangzhi Cup” English Teaching Competition in Qilu Hospital of Shandong University, Third Prize, July 2013: Excellent Graduate of Shandong Province, Oct. 2009: National Scholarship

Publications Top Notes šŸ“

  • Xuji Jiang, Chuanli Feng, Wanying Sun, Teng Zhang*, Baoxia Cui. “The top 100 most cited articles on fertility-sparing treatments for cervical cancer: A bibliometric analysis.” Heliyon, 10(11), 2024.

 

  • Zhonghao Mao, Bingyu Wang, Teng Zhang, Baoxia Cui*. “The roles of m6A methylation in cervical cancer: functions, molecular mechanisms, and clinical applications.” Cell Death and Disease, 2023, 14(734).

 

  • Teng Zhang, Jun Jiao, Xinlin Jiao, Lu Zhao, Xinli Tian, Qing Zhang, Daoxin Ma, Baoxia Cui*. “Aberrant frequency of TNFR2+ Treg and related cytokines in patients with CIN and cervical cancer.” Oncotarget, 2017, 9(4).

 

  • Bingyu Wang, Zhonghao Mao, Jinwen Ye, Xinlin Jiao, Teng Zhang, Qi Wang, Sai Han, Youzhong Zhang, Chunling Wang, Taotao Dong, Baoxia Cui. “Glycolysis Induced by METTL14 Is Essential for Macrophage Phagocytosis and Phenotype in Cervical Cancer.” The Journal of Immunology, 2024, 15(212).

 

  • Zhang W, Tian X, Mumtahana F, Jiao J, Zhang T, Croce K.D., Cui B*. “The existence of Th22, pure Th17 and Th1 cells in CIN and Cervical Cancer along with their frequency variation in different stages of cervical cancer.” BMC Cancer, 2015, 15,717.

 

  • Jun Jiao, Teng Zhang, Xinlin Jiao, Tingting Huang, Lu Zhao, Daoxin Ma, Baoxia Cui*. “hsa_circ_0000745 promotes cervical cancer by increasing cell proliferation, migration, and invasion.” J Cell Physiol, 2019, 1-9.

 

  • Xinlin Jiao, Siying Zhang, Jun Jiao, Teng Zhang, Wenjie Qu, Guy Mutangala Muloye, Beihua Kong, Qing Zhang, Baoxia Cui*. “Promoter methylation of SEPT9 as a potential biomarker for early detection of cervical cancer and its overexpression predicts radioresistance.” Clin Epigenetics, 2019, 11(120).